Navigation Links
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Date:11/15/2007

- Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure Rate for Biaxin(R), a Current Standard of

Care Treatment - - Trial CL-05 and Trial CL-06 to Form the Core of New Drug Application -

CHICAGO, Nov. 15 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States. The primary efficacy endpoint of statistical non-inferiority in the clinical cure rate at the test-of-cure visit was achieved. The study results showed that cethromycin cured 94.0% of patients with CAP, compared to Biaxin(R) (clarithromycin), a current standard of care treatment for CAP, which cured 93.8% of studied patients in the per protocol population. In the modified intent to treat population, cethromycin cured 83.1% of patients and Biaxin cured 81.1%. Cethromycin also demonstrated favorable safety results, with reported side effects similar to or less than those seen with Biaxin.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )

"We are very excited to have met all of our endpoints in Trial CL-05, and we are pleased to have successfully completed the clinical development program of cethromycin. The results attained in this trial, along with the positive results achieved in Trial CL-06 reported in June of this y
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
6. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... Median time to pain progression is 66.1 weeks ... the placebo arm --,Hazard ratio of 0.64 (95% ... relative risk of pain progression, MARTINSRIED/MUNICH, Germany, May ... -- GPC Biotech AG and,Pharmion Corporation today announced ...
... analysis shows nearly nine out of ten patients ... of 12 months, WASHINGTON, D.C., May 22, 2007 ... extension study (303),presented at the British Society of ... showed Shire plc's,Lialda(mesalamine) is well tolerated in mild ...
Cached Medicine Technology:Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... As reported by the New ... a significant number of severe adverse events such as ... even death from the highly-promoted and costly immune-system drug, ... report , a regulatory filing revealed that the ... was almost 14% of prescriptions, up from 9.1% in ...
(Date:7/11/2014)... New York, NY (PRWEB) July 11, 2014 ... growth during the five years to 2014 on the ... Regulations of 2010 prompted farmers to dedicate a larger ... in ethanol production. More specifically, the regulations required the ... Similarly, rapidly expanding biofuel production in the United States ...
(Date:7/11/2014)... 11, 2014 Ticket Down is a reliable source ... Mountain View, CA. Over the years Luke Bryan has been ... only does he do well at award shows, but each summer, ... most anticipated tours of the genre and this summer is more ... can compare to the popularity and success that is currently entitled ...
(Date:7/11/2014)... Europe is one of the largest consumers of ... land area. The agricultural sector is a significant user ... of the total water use. The scale and importance ... but far from negligible in most northern ones. , ... of the water use in most countries, while in ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3
... in ... underserved areas, WOODLAND HILLS, Calif., Dec. 11 ... in end of,year donations to various food banks throughout California. An unrestricted,check ... California to assist vulnerable populations., Blue Cross employees will visit each ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage ... cancer and inflammatory diseases, today,announced that the ... accepted its,Investigational New Drug (IND) application for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ...
... WARSAW, Ind., Dec. 11 Zimmer Holdings, Inc.,(NYSE: ... industry, announced,today that its Premarket Approval (PMA) application for ... the Food and Drug,Administration., "A number of orthopaedic ... be one of only two companies that can offer ...
... Recent developments regarding,North Carolina,s organ and tissue donation ... to hire Corder Philips to aid in the,campaign ... developments include a grant received from the License ... update their online,registry and increase outreach efforts by ...
... Calif., Dec. 11 Varian Medical,Systems (NYSE: VAR ... the company,s Annual Meeting of Stockholders for February 14,2008 ... meeting will be held at,the Sheraton Palo Alto, 625 ... The meeting will be webcast by CCBN and ...
... regions activated by beliefs and human feelings, study shows ... disbelief and uncertainty activate distinct areas of the brain, ... online in the Annals of Neurology . ... was monitored using functional magnetci resonance imaging (fMRI) while ...
Cached Medicine News:Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 2Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 3Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 4Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 2Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 3Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 4Health News:North Carolina Coalition on Donation Selects Corder Philips for Newest Campaign 2Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Personal Convictions May Control Both Behavior and Emotions 2
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Plastic Citrate Tube, .109M / 3.2%...
Inquire...
Medicine Products: